179 related articles for article (PubMed ID: 25443341)
1. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.
Ford N; Swan T; Beyer P; Hirnschall G; Easterbrook P; Wiktor S
J Hepatol; 2014 Nov; 61(1 Suppl):S132-8. PubMed ID: 25443341
[TBL] [Abstract][Full Text] [Related]
2. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
Ford N; Wiktor S; Kaplan K; Andrieux-Meyer I; Hill A; Radhakrishnan P; Londeix P; Forette C; Momenghalibaf A; Verster A; Swan T
Int J Drug Policy; 2015 Nov; 26(11):1088-93. PubMed ID: 26074094
[TBL] [Abstract][Full Text] [Related]
3. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
4. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
Hézode C
J Viral Hepat; 2017 Feb; 24(2):92-101. PubMed ID: 27862695
[TBL] [Abstract][Full Text] [Related]
5. A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
Mathur P; Comstock E; McSweegan E; Mercer N; Kumar NS; Kottilil S
Antiviral Res; 2017 Oct; 146():184-190. PubMed ID: 28927676
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
7. Pathways to ensure universal and affordable access to hepatitis C treatment.
Douglass CH; Pedrana A; Lazarus JV; 't Hoen EFM; Hammad R; Leite RB; Hill A; Hellard M
BMC Med; 2018 Oct; 16(1):175. PubMed ID: 30296935
[TBL] [Abstract][Full Text] [Related]
8. New hepatitis C therapies: the toolbox, strategies, and challenges.
Pawlotsky JM
Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
[TBL] [Abstract][Full Text] [Related]
9. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Assefa Y; Hill PS; Ulikpan A; Williams OD
Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
[TBL] [Abstract][Full Text] [Related]
10. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Hill A; Khoo S; Fortunak J; Simmons B; Ford N
Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
[TBL] [Abstract][Full Text] [Related]
11. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
El Sherif O; Afhdal N; Curry M
J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
[TBL] [Abstract][Full Text] [Related]
12. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
13. HCV management in resource-constrained countries.
Lim SG
Hepatol Int; 2017 May; 11(3):245-254. PubMed ID: 28224352
[TBL] [Abstract][Full Text] [Related]
14. New Therapies for Hepatitis C Virus.
Polenakovik H
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
[TBL] [Abstract][Full Text] [Related]
15. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
16. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
18. HCV transmission in industrialized countries and resource-constrained areas.
Thursz M; Fontanet A
Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):28-35. PubMed ID: 24080775
[TBL] [Abstract][Full Text] [Related]
19. Revolution in hepatitis C antiviral therapy.
Sadler MD; Lee SS
Br Med Bull; 2015 Mar; 113(1):31-44. PubMed ID: 25680808
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
